MaxCyte, Inc. Result of Annual General Meeting (5694N)

TIDMMXCT

RNS Number : 5694N

MaxCyte, Inc.

27 October 2016

MaxCyte, Inc.

("MaxCyte" or the "Company")

Result of Annual General Meeting

Maryland, USA - 27 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines, products and services, announces that at its Annual General Meeting held yesterday at 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878 USA, all resolutions were duly passed.

- ENDS -

For further information please contact:

 
 MaxCyte                                [phone] 
 Doug Doerfler, Chief Executive 
  Officer 
  Ron Holtz, Chief Financial 
  Officer 
 
 Nominated Adviser and Broker 
  Panmure Gordon 
  Freddy Crossley (Corporate 
  Finance) 
  Fabien Holler 
  Duncan Monteith 
  Tom Salvesen (Corporate Broking)      [phone] 
 
 Financial PR Advisor                   [phone] 
  Consilium Strategic Communications     [e-mail] 
 Mary-Jane Elliott 
  Chris Welsh 
  Lindsey Neville 
 

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit http://www.maxcyte.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGLQLLLQBFLFBV

(END) Dow Jones Newswires

October 27, 2016 02:00 ET (06:00 GMT)